NCT00117273

Brief Summary

This is a randomized, open-label study to evaluate pituitary ovarian suppression in healthy, reproductive-aged women using three different regimens of oral contraceptives (OCs). Two extended regimen OCs, Seasonale (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days followed by 7 days of placebo), and Seasonique (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days followed by 7 days of ethinyl estradiol 0.01 mg), and a 28-day regimen OC, Portia (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 21 days followed by 7 days of placebo).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
36

participants targeted

Target at below P25 for phase_3 healthy

Timeline
Completed

Started Jun 2005

Typical duration for phase_3 healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2005

Completed
29 days until next milestone

First Submitted

Initial submission to the registry

June 30, 2005

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 6, 2005

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2006

Completed
Last Updated

May 9, 2014

Status Verified

May 1, 2014

First QC Date

June 30, 2005

Last Update Submit

May 8, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • Compare differences in hormone patterns (follicle stimulating hormone [FSH], luteinizing hormone [LH], inhibin-B, and estradiol)

    Before, during and after the 7-day hormone free interval or EE-supplemented interval

Secondary Outcomes (2)

  • Compare the differences in hormone withdrawal symptoms

    Before, during and after the 7-day hormone free interval or EE-supplemented interval

  • Compare differences in ovarian follicular development

    Before, during and after the 7-day hormone free interval or EE-supplemented intervals

Study Arms (3)

1

EXPERIMENTAL
Drug: Seasonique (LNG/EE and EE)

2

ACTIVE COMPARATOR
Drug: Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)]

3

ACTIVE COMPARATOR
Drug: Portia (LNG/EE)

Interventions

1 tablet daily

1

1 tablet daily x 28 days

3

Eligibility Criteria

Age18 Years - 35 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Premenopausal
  • Not pregnant or breastfeeding
  • Weight \<200 lbs
  • Currently taking oral contraceptives in the standard 28-day regimen for at least two months

You may not qualify if:

  • Any contraindication to the use of oral contraceptives
  • Pregnancy within the last 3 months
  • Smoking \> 10 cigarettes per day

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Duramed Investigational Site

Temple, Texas, 76508, United States

Location

Related Links

MeSH Terms

Interventions

SeasonaleLevonorgestrelSeasoniqueEthinyl Estradiol-Norgestrel Combination

Intervention Hierarchy (Ancestors)

NorgestrelNorpregnenesNorpregnanesNorsteroidsSteroidsFused-Ring CompoundsPolycyclic CompoundsEthinyl EstradiolNorpregnatrienesEstrogenic Steroids, AlkylatedEstradiol CongenersGonadal Steroid HormonesGonadal HormonesHormonesHormones, Hormone Substitutes, and Hormone Antagonists

Study Officials

  • Duramed Protocol Chair

    Duramed Research, Inc.

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

June 30, 2005

First Posted

July 6, 2005

Study Start

June 1, 2005

Study Completion

June 1, 2006

Last Updated

May 9, 2014

Record last verified: 2014-05

Locations